New insights on sorafenib resistance in liver cancer with correlation of individualized therapy
Authors:
- 1 August 2020
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1874 (1) , 188382
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Commission of Shanghai Municipality
This publication has 135 references indexed in Scilit:
- Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular CarcinomaGastroenterology, 2013
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trialEuropean Journal of Cancer, 2012
- Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectivesEMBO Molecular Medicine, 2012
- Functional genomics reveal that the serine synthesis pathway is essential in breast cancerNature, 2011
- Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesisNature Genetics, 2011
- Inflammation and Liver CancerAnnals of the New York Academy of Sciences, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002